Enlarge image
Corona vaccine (archive image)
Photo: Zydus Cadila
According to the Robert Koch Institute (RKI), the number of known infections in Germany has increased by
78,698
to over 31.3 million.
That is 24,000 fewer cases than on Tuesday a week ago, when 102,698 infections were recorded.
The
seven-day incidence
is
381.5
.
The RKI reports
170 more deaths
related to the corona virus.
The known total is 145,028.
The health ministers of the federal states want to speak at a virtual conference with Federal Minister Karl Lauterbach (SPD) on Tuesday about the draft of the new Infection Protection Act.
According to the Saxony-Anhalt Ministry of Social Affairs, which currently chairs the Conference of Health Ministers, this is the only item on the agenda.
According to the draft law, a mask requirement on buses, trains and planes should continue to apply nationwide, as well as a new requirement for masks and tests in hospitals and care facilities.
From October, the federal states should also be able to decide for themselves whether they also require masks in publicly accessible indoor areas.
According to the State Ministry of Social Affairs, there should be an exchange as to whether the planned measures are sufficient or should be tightened up.
However, no decision is planned.
Omicron vaccine in final phase
Parts of the FDP and the CDU have recently criticized and requested changes to the federal government’s corona protection concept for autumn and winter.
The FDP parliamentary group leadership defended the plans.
Meanwhile, a vaccine adapted to the omicron variants BA.4 and BA.5 is drawing near.
The pharmaceutical company Biontech announced that a corresponding clinical study would start this month.
If the responsible authorities approve this, the first cans could be delivered from October, said CEO and co-founder Ugur Sahin on Monday in Mainz.
Biontech had previously developed a vaccine adapted to the BA.1 variant.
The EU medicines agency EMA started the test procedure for this vaccine from the manufacturers Biontech and Pfizer in mid-June.
jok/Reuters
